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Abstract
Recessive dystrophic epidermolysis bullosa (RDEB) is a genodermatosis that leads to skin fra-
gility and chronic wound formation. Patients with RDEB are at risk for cutaneous squamous 
cell carcinoma (SCC) which is a major cause of morbidity and mortality in these patients. No 
standard of care exists for the treatment of SCC in this patient population and therapy is based 
on anecdotal reports and expert opinion. We report a 32-year-old man with RDEB with previ-
ously localized SCC who later developed metastatic SCC. He was started on cemiplimab (an 
immune checkpoint inhibitor) 350 mg IV every 3 weeks. An objective radiological response 
was noted within 3 cycles. On 14 months follow-up, there was a durable response to treatment 
clinically and on imaging, without immune-related adverse events. To our knowledge, this is 
the first case report describing safe administration of immune checkpoint inhibitors in a pa-
tient with RDEB with objective and durable response of metastatic SCC. Larger case series and 
controlled clinical trials are needed to further investigate these medications in the RDEB pop-
ulation, given their high burden of aggressive and often lethal SCC.
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Introduction
Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic skin disease caused 
by mutations in the gene COL7A1, leading to absent or defective type VII collagen, with skin 
fragility and resulting chronic wounds. These patients may develop extremely aggressive and 
often metastatic cutaneous squamous cell carcinoma (SCC). The risk for developing these 
lesions increases dramatically in the third decade; malignancy is often the cause of death [1]. 
Surgical treatment is the mainstay for localized tumors. There is no optimal therapy for 
advanced or metastatic SCC in this patient population given the partial short-lived response 
with conventional chemotherapy and the absence of controlled trials [2].
Immune checkpoint inhibitors block receptors in the tumor microenvironment respon-
sible for immune suppression and malignancy progression. Cemiplimab is a monoclonal 
antibody that blocks programmed death-1 (PD-1) receptors leading to reactivation of the 
immune system against tumor cells. It was approved by the Food and Drug Administration in 
September 2018 to treat locally advanced and metastatic cutaneous SCC [3]. However, no 
reports currently exist in the literature describing its safety and efficacy in RDEB patients. We 
present a case of an RDEB patient with an objective durable response to cemiplimab therapy 
for metastatic SCC.
Case Presentation
A 32-year-old male presented with severe RDEB, confirmed via genetic testing (homo-
zygous for c.8440C>T [p.R2814X] in exon 114 of COL7A1). He had a prior history of multiple 
SCCs on the lower back and right hand. Initial treatments of localized SCCs included numerous 
surgical resections. Recurrences were treated with topical imiquimod 5%, 5-fluorouracil and 
calcipotriene followed by intradermal injection with 5-fluorouracil and methotrexate. 
However, the patient subsequently developed a large axillary lymph node and a new large 
fungating eroded nodule on the right forearm, positive for invasive SCC on shave biopsy.
The patient was treated several years prior with autologous keratinocyte skin grafts 
corrected with a retroviral vector locally to the upper back [4] and intradermal injections of 
autologous fibroblasts corrected with a lentiviral vector to the posterior neck and foot. SCC 
tissue samples and serum samples were negative for presence of these viruses.
Prior to initiation of therapy, positron emission tomography/computed tomography 
(PET/CT) with [18F]fluorodeoxyglucose (FDG) revealed several foci of intense uptake along 
the right upper extremity including the right axilla, anterior right forearm, and dorsal and 
volar surfaces of the distal right forearm and hand (Fig. 1A), consistent with SCC sites. PET/
CT also revealed numerous foci of mildly increased FDG uptake associated with skin thick-
ening throughout the body, likely related to RDEB.
The patient commenced cemiplimab 350 mg IV every 3 weeks, with a single treatment of 
radiotherapy (total of 16 Gy) to the right axilla and forearm. Two months after initiation of 
cemiplimab, repeat FDG-PET/CT showed marked metabolic response at the known sites of 
SCC in the right upper extremity and right axillary lymph nodes (Fig. 1B). There was no signif-
icant change in the numerous foci of mildly increased FDG uptake of the skin. No cutaneous 
lesions were visible on exam and no lymphadenopathy was apparent. Scans every 3 months 
were without evidence of SCC.
The patient reported mild nausea and fatigue, but denied any other side effects, including 
worsening RDEB wounds. There were no immune-related adverse events reported during or 
after initiation of immunotherapy. At the time of this report, he continues cemiplimab dosing 
every 3 weeks. The response has been sustained for 14 months.
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Discussion
SCC is a major cause of morbidity and mortality in RDEB patients. Median survival after 
SCC diagnosis is estimated at 2.4 years; over one third are estimated to develop metastatic 
disease [1]. SCC usually arises at chronic wounds and shows resistance and refractoriness to 
topical treatments as well as a pattern of recurrence after surgical resection. Chemotherapies 
have been described as a palliative approach in locally advanced and metastatic disease, with 
inconsistent outcomes [2]. Chemotherapies and targeted epidermal growth factor receptor 
inhibitor cetuximab have been described to be effective for metastatic SCC in RDEB patient 
[5]. However, these therapies typically incur a substantial risk for severe infections due to the 
need for indwelling vascular accesses, bone marrow suppression with neutropenia, and cuta-
neous side effects such as desquamation, mucositis, and severe (grade 3 to 4) acneiform reac-
tions, which could be disastrous in patients with severe RDEB (Table 1) [2].
Cemiplimab is a monoclonal antibody that targets PD-1 receptors on immune cells 
leading to augmentation of anti-tumor response. In an expansion cohort phase 1 study and a 
phase 2 single arm cohort, it has shown durable tumor responses in patients with cutaneous 
metastatic SCC without observed severe skin reactions, increased risk of neutropenia, or 
serious infections, which has led to its approval as a monotherapy of locally advanced and 
Fig. 1. PET/CT images prior to and following therapy with cemiplimab. A Anterior volume-rendered maxi-
mum activity-projection FDG-PET images show intense FDG uptake in the right upper extremity and right 
axillary lymph nodes on the pretherapy scan. The largest and most intense lesion corresponded to a FDG-
avid soft tissue mass in the anterior right forearm (5.2 × 4.6 cm), with a maximum standardized uptake val-
ue (SUVmax) of 33.3. A large conglomeration of right axillary lymph nodes with central photopenia (6.7 × 3.4 
cm, SUVmax of 22.8) is also present. Transaxial images consisting of fused PET/CT (left) and PET (right) at the 
level of axilla show intense FDG uptake within the right axillary lymph nodes. B PET/CT images following 
therapy demonstrated marked partial metabolic response. FDG uptake within the anterior right forearm, 
decreased in size to 1.2 × 0.6 cm and FDG uptake (SUVmax of 5.7). The necrotic right axillary lymph nodes have 
decreased in size (2.5 × 0.9 cm) and FDG uptake (SUVmax of 6).
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metastatic SCC [3, 8]. However, clinical trials of cemiplimab did not include RDEB patients. 
Given the significant risk of treatment complications associated with conventional chemo-
therapies and tyrosine kinase inhibitors, there is an unmet need for effective and safe ther-
apies in metastatic SCC in patients with RDEB.
The loss of type VII collagen results in a fragile dermal-epidermal skin barrier causing 
development of chronically colonized and infected cutaneous wounds with multiple drug-
resistant bacteria that can often lead to sepsis [9]. This risk can be exacerbated when RDEB 
patients are treated with chemotherapies, which suppresses the bone marrow, and with 
tyrosine kinase inhibitors that can cause irritation of the skin barrier due to mucositis. The 
use of cemiplimab does not usually require indwelling vascular access. Furthermore, there 
have been only mild and minimal skin adverse events associated with the use of cemiplimab 
without observed bone marrow suppression.
Our patient demonstrated a sustained radiological response for 14 months, with minimal 
side effects and no immune-related adverse effects, which is promising. However, additional 
larger case studies and controlled trials are needed to confirm the safety and efficacy of 
cemiplimab in RDEB patients with cutaneous metastatic SCC.
Conclusion
To our knowledge, this is the first report of outcomes of treatment with a PD-1 inhibitor 
in a patient with metastatic SCC and RDEB. This report is important as patients with RDEB 
have high risk of metastatic SCC, which is a major cause of morbidity and mortality. No 
standard of care exists regarding these patients; therefore, we report the safety and efficacy 
with durable response (14 months) in one patient. This report should be interpreted with 
caution, as larger studies are needed to confirm the safety and efficacy of this approach.
Statement of Ethics
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Table 1. Comparison of conventional squamous cell carcinoma therapies and risks of severe cutaneous side effects
Therapy for squamous cell carcinoma Side effects
Chemotherapies: alkylating agents, anthracyclines, antimetabolites, 
antineoplastics [6]
– neutropenia
– severe skin infections
– severe septicemia




– increased risk of infection and septicemia
Risk factors in patients with recessive dystrophic epidermolysis bullosa
Increased skin fragility
Large chronic wounds
Frequent wound infections, often with multi-drug-resistant bacteria
Chronic inflammatory state
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